Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 2Completed 2Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 31Sarcoma 5Thoracic 4Gynecologic 3Gastrointestinal 3Breast 3Other solid neoplasm 2Head & Neck 2Myeloid 1Lymphoid 1Genitourinary 1CNS 1

Conditions

Lymphoma 156Lymphoma, Non-Hodgkin 140Leukemia, Lymphocytic, Chronic, B-Cell 136Precursor Cell Lymphoblastic Leukemia-Lymphoma 132Lymphoma, Follicular 112Lymphoma, Large B-Cell, Diffuse 111Lymphoma, Mantle-Cell 75Lymphoma, B-Cell 73Hodgkin Disease 63Multiple Myeloma 58Leukemia 55Burkitt Lymphoma 51Recurrence 48Lymphoma, B-Cell, Marginal Zone 48Leukemia, Myeloid, Acute 47Neoplasms 45Myelodysplastic Syndromes 42Hematologic Neoplasms 34Waldenstrom Macroglobulinemia 28Leukemia, Myelogenous, Chronic, BCR-ABL Positive 18Lymphoma, T-Cell 17Leukemia, Biphenotypic, Acute 16Leukemia, B-Cell 16Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 15Mycosis Fungoides 15Lymphoproliferative Disorders 15Lymphoma, T-Cell, Peripheral 15Myeloproliferative Disorders 14Lymphoma, T-Cell, Cutaneous 14Breast Neoplasms 14

Interventions

ruxolitinib 1avelumab 1Pemetrexed 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Uveal Melanoma × Lymphoid × Clear all
NCT04328844 2026-03-30

A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

iOnctura

Phase 1 Active not recruiting
210 enrolled
DermatologicLymphoidMyeloidOther solid neoplasmThoracic

Uveal Melanoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Mesothelioma, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡